Navigation Links
Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients
Date:10/26/2008

ation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., USA, and its Web site is http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the clinical development of and the potential market for vicriviroc. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details of these and other risks and uncertainties that may impact forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Item 8.01 of the company's 8-K filed Oct. 21, 2008.

References

(1) Coakley E, et al. Second International Workshop Targeting HIV Entry. Oct. 20-21, 2006; Boston, MA, USA; No. 8.

(2) Dunkle LM, Greaves WL, et al. Long-Term Safety of Vicriviroc. 4
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... MASON, Ohio , Dec. 23, 2014 /PRNewswire/ ... industry-leading treatment decision support to healthcare providers for ... that it has secured $30 million in equity ... Virginia C. Drosos , President and Chief ... increased clinical adoption and development of Assurex Health,s ...
(Date:12/24/2014)... Va. , Dec. 23, 2014  The ... diastolic blood pressure target for people with diabetes ... moderate or high doses of statins, in keeping ... management enacted by the American College of Cardiology ... are reflected in the most recent changes to ...
(Date:12/24/2014)... , Dec. 23, 2014 In response to urgent ... of Sierra Leone , Direct Relief delivered ... for the treatment of local health workers who contract ... new dedicated Ebola care center was constructed for foreign health ... is not available for local Sierra Leonean health workers. ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) today announced ... Citi 2011 Global Health Care Conference on Thursday, ... Hilton New York Hotel in New York City. Cowen ... 7, 2011 at 4:45 p.m. Eastern Time at The Boston ...
... March 1, 2011 / PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) ... biotechnology and medical device R&D outsourcing company with operations ... it will release financial results for the fourth quarter ... on Tuesday, March 8, 2011 (which will be Wednesday ...
Cached Medicine Technology:Optimer Pharmaceuticals to Present at March 2011 Investor Conferences 2WuXi PharmaTech Schedules Fourth-Quarter 2010 Earnings Release 2
(Date:12/25/2014)... (PRWEB) December 26, 2014 The report ... 2023” focuses on the current treatment landscape, unmet needs, ... market. TS-1 is an anti-cancer drug which is typically ... and is also used for treating gastric cancer and ... otastat potassium. The drug was first approved in 1999 ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 The short film ... was created in honor of a true 9/11 hero, Welles ... film festivals including the 24 hours of Nuremberg International Short ... Bangladesh. , Actress, screenwriter and director Luciana Lagana ... this film together with her husband, Gregory Graham ...
(Date:12/25/2014)... December 25, 2014 Recently, LunaDress.co.uk has updated its ... and related accessories. Now, all of the models at LunaDress.co.uk come ... a groom lifts the wedding veil can turn out to be ... charm. A wedding veil can always bring surprise to a wedding. ... on how to choose veils for a big day . ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 (HealthDay ... of youth" drug that can delay the effects of aging ... suggests. Seniors received a significant boost to their immune ... pathway linked to aging and immune function, researchers with the ... a version of the drug rapamycin, improved the seniors, immune ...
(Date:12/25/2014)... 2014 Residents at Abernethy ... showed their generous spirit by providing holiday gifts ... Parenting Network- Grandparents Raising Grandchildren program. , Following ... the largest Christmas tree on the campus of ... residents of the Abernethy Village Association (AVA). Each ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Retirement Community Residents Make Impact During Holiday Season 2
... Health Organization (WHO) figures show that each year an ... in the world. The growth of this disease remains ... of HIV patients (nearly 13% compared with less than ... the world is experiencing accelerating advance of a deadly ...
... Dog On It! Fortified Juice Beverages for Kids Pledges up to ... $650,000 for Type 1 Diabetes Research, ... Dog On,It! fortified juice beverage for kids, announced today the launch ... the world,s leading charitable funder of type 1,diabetes research., As ...
... RICHMOND, Calif., March 5 Transcept,Pharmaceuticals, Inc. today ... Chief Financial Officer, will present at Cowen and ... Marriott Copley Place on,Thursday, March 20, 2008 at ... Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical ...
... On Saturday, March,29 at 8:00 am, the Bowen ... Waters Park in Annapolis to raise money to fight ... experience a beautiful 5K,waterfront course complete with activities for ... proceeds from the event go toward the Bowen,Foundation, an ...
... for oil exploration now researchers at The University ... steroid test using hydropyrolysis. , The process which ... and make-up of a sample has been refined ... tests for detecting levels of illicit steroids in urine. ...
... Corporation,(ADAMS), the leading provider of program management and ... of Deborah (Debbie) J.,Aiken and Brandon L. Cannaday ... have joined ADAMS as Associate Project Managers within ... both based out of ADAMS,Cleveland, Ohio office location ...
Cached Medicine News:Health News:A new more effective tuberculosis screening test for HIV victims 2Health News:A new more effective tuberculosis screening test for HIV victims 3Health News:White Hat Brands, Juvenile Diabetes Research Foundation Offer the 'Juice' on New Partnership 2Health News:White Hat Brands, Juvenile Diabetes Research Foundation Offer the 'Juice' on New Partnership 3Health News:Inaugural Bowen Foundation Run/Walk to Fight Autism in Maryland Set for Saturday, March 29 2Health News:New steroid test uses oil exploration technique 2Health News:ADAMS Welcomes Debbie Aiken and Brandon Cannaday to the Firm's Staff as Associate Project Managers 2Health News:ADAMS Welcomes Debbie Aiken and Brandon Cannaday to the Firm's Staff as Associate Project Managers 3
... Cardiology specific EMR / PM system ... nationwide,enabling more effective patient care decisions.,AcerMed's ... clinicians with critical information on a ... care.,Our Cardiology specific clinical pathways have ...
...
... is estimated that 25% of women and 15% ... United States, more than half of adults over ... unsightly venous disease., The VenaCure Laser Vein Treatment ... the treatment of varicose veins. VenaCure offers your ...
ELVeS is a new minimally-invasive laser treatment for patients with superficial vein reflux of the greater saphenous vein. The ELVeS laser treatment offers your patients an effective out-patient alt...
Medicine Products: